21 hrs ago
Alexion Pharmaceuticals Receives Consensus Recommendation of...
Shares of Alexion Pharmaceuticals have received an average rating of "Buy" from the eighteen analysts that are covering the stock, StockRatingsNetwork reports .
Wed Aug 20, 2014
Insider Selling: Alexion Pharmaceuticals CEO Leonard Bell Sells 70,000 Shares of Stock
Alexion Pharmaceuticals CEO Leonard Bell unloaded 70,000 shares of the stock on the open market in a transaction dated Friday, August 15th.
Mon Aug 18, 2014
Insider Selling: Alexion Pharmaceuticals CEO Unloads 70,000 Shares of Stock
Alexion Pharmaceuticals CEO Leonard Bell unloaded 70,000 shares of the company's stock in a transaction dated Friday, August 15th.
Weekly FDA Enforcement Report For Drugs 8/13/14
The Food and Drug Administration has released its Drug product Enforcement Report for August 13, 2014.
Thu Aug 14, 2014
Alexion CEO Receives Nearly $17 Million for Sale of Company Stock
The CEO of Alexion Pharmaceuticals Inc , Leonard Bell, sold more than 100,000 shares of company stock Wednesday for nearly $17 million.
Wed Aug 13, 2014
Insider Selling: Alexion Pharmaceuticals CEO Sells 80,458 Shares of Stock
Alexion Pharmaceuticals CEO Leonard Bell sold 80,458 shares of the stock on the open market in a transaction that occurred on Tuesday, August 12th.
Insider Selling: Leonard Bell Unloads 105,000 Shares of Alexion Pharmaceuticals Stock
Alexion Pharmaceuticals CEO Leonard Bell sold 105,000 shares of the company's stock in a transaction dated Wednesday, August 13th.
Customer Interaction Solutions
Researchers to Present New Data on Asfotase Alfa in Pediatric...
Alexion Pharmaceuticals, Inc. today announced that new data from multiple studies of asfotase alfa in pediatric patients with hypophosphatasia will be presented at the American Society for Bone and Mineral Research 2014 Annual Meeting, which takes place September 12-15, 2014 in Houston, Texas.
Tue Aug 05, 2014
Alexion Pharmaceuticals CFO Vikas Sinha Sells 1,525 Shares
Alexion Pharmaceuticals CFO Vikas Sinha sold 1,525 shares of the stock in a transaction that occurred on Monday, August 4th.
Alexion Pharmaceuticals EVP Sells $213,142 in Stock
Alexion Pharmaceuticals EVP David Hallal unloaded 1,349 shares of Alexion Pharmaceuticals stock in a transaction dated Monday, August 4th.
EC Designates Orphan Status To Alexion's Soliris For MG
Alexion Pharmaceuticals reported that the European Commission has designated its drug Soliris orphan drug status for the treatment of rare disease Myasthenia Gravis .
Fri Aug 01, 2014
Alexion Pharmaceuticals Inc. Release: European Commission Grants...
Alexion Pharmaceuticals today announced that the European Commission has granted orphan drug designation to SolirisA for the treatment of patients with Myasthenia Gravis , a rare, debilitating neurologic disorder caused by uncontrolled complement activation.
Mon Jul 28, 2014
Alexion Looks Better After Q2 Earnings
Alexion reported earnings last week that failed to excite investors as the share price went down in the next two days.
Fri Jul 25, 2014
Stifel Nicolaus Reiterates Buy Rating for Alexion Pharmaceuticals
's stock had its "buy" rating reiterated by investment analysts at Stifel Nicolaus in a note issued to investors on Friday.
The Hartford Courant
Alexion Profits Up 38% From A Year Earlier
Alexion Pharmaceuticals, the highly successful biotech company headquartered in Cheshire, grew profits by more than $70 million in the second quarter of 2014 compared with the same period a year earlier, as more patients start on Soliris, which is then needed for the rest of their lives.
Thu Jul 24, 2014
Thursday Sector Laggards: Materials, Healthcare
The worst performing sector as of midday Thursday is the Materials sector, not showing much of a gain.
Investor's Business Daily
Celgene, Alexion Beat Estimates, But Biotechs Fall
Big-cap biotechs Celgene and Alexion Pharmaceuticals modestly beat Q2 estimates and raised their guidance early Thursday, but their shares tumbled as Wall Street seemed to turn against the sector.
Alexion Pharmaceuticals' (ALXN) CEO Leonard Bell on Q2 2014 Results - Earnings Call Transcript
Good morning, and welcome to the Alexion Pharmaceuticals, Incorporated Second Quarter 2014 Results Conference Call.
Alexion Pharmaceuticals Inc. Release: European Medicines Agency...
Alexion Pharmaceuticals, Inc. today announced that the Marketing Authorization Application for asfotase alfa, an investigational, first-in-class targeted enzyme replacement therapy for the treatment of hypophosphatasia , has been validated and granted accelerated assessment by the European Medicines Agency .
Press release distribution, EDGAR filing, XBRL, regulatory filings
The International Center for Dispute R... )--Ap19 FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECU... Resumen: La Agencia Europea del Medicamento acepta la solicitud de autorizacin de marketing de Asfotasa Alfa como tratamiento ... (more)